BRAF F595L
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene BRAF
Variant F595L
Impact List missense
Protein Effect loss of function
Gene Variant Descriptions BRAF F595L lies within the protein kinase domain of the Braf protein (UniProt.org). F595L results in reduced Braf kinase activity (PMID: 28783719, PMID: 15035987), but works cooperatively with oncogenic Ras to activate MEK/ERK signaling, and is transforming in cell culture (PMID: 15035987, PMID: 26582644, PMID: 29533785).
Associated Drug Resistance
Category Variants Paths

BRAF mutant BRAF F595X BRAF F595L

BRAF mutant BRAF inact mut BRAF F595L

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_004333.6
gDNA chr7:g.140753352A>G
cDNA c.1783T>C
Protein p.F595L
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001354609.1 chr7:g.140753352A>G c.1783T>C p.F595L RefSeq GRCh38/hg38
NM_004333.5 chr7:g.140753352A>G c.1783T>C p.F595L RefSeq GRCh38/hg38
NM_001378468.1 chr7:g.140753352A>G c.1783T>C p.F595L RefSeq GRCh38/hg38
NM_001354609.2 chr7:g.140753352A>G c.1783T>C p.F595L RefSeq GRCh38/hg38
NM_004333 chr7:g.140753352A>G c.1783T>C p.F595L RefSeq GRCh38/hg38
NM_001378474.1 chr7:g.140753352A>G c.1783T>C p.F595L RefSeq GRCh38/hg38
XM_005250045 chr7:g.140753352A>G c.1783T>C p.F595L RefSeq GRCh38/hg38
NM_004333.6 chr7:g.140753352A>G c.1783T>C p.F595L RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRAF F595L Advanced Solid Tumor resistant Vemurafenib Preclinical - Cell culture Actionable In a preclinical study, treatment with Zelboraf (vemurafenib) did not reduce activation of Mek and Erk by BRAF F595L in transformed cells in culture (PMID: 26582644). 26582644
BRAF F595L colorectal cancer not predictive Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Case Reports/Case Series Actionable In a clinical study, the combination of Vectibix (panitumumab) with FOLFOX as a first-line therapy resulted in a partial response with progression-free survival of 10.2 months in a patient with metastatic colorectal cancer harboring BRAF F595L (PMID: 31515458). 31515458
BRAF F595L intrahepatic cholangiocarcinoma predicted - sensitive Cetuximab + Trametinib Case Reports/Case Series Actionable In a clinical case study, treatment with the combination of Erbitux (cetuximab) and Mekinist (trametinib) followed by Erbitux (cetuximab) monotherapy resulted in an objective response at a follow-up of 6 months in a patient with intrahepatic cholangiocarcinoma harboring BRAF F595L along with an IDH2 R172W (PMID: 39516363). 39516363